Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction

Executive Summary

Analysts and investors also voice excitement about the THR-beta agonist's lipid-lowering effects to date. For Madrigal, the key will be replicating its 12-week data at 36 weeks, when the trial ends.

Advertisement

Related Content

Galectin Offers Subgroup Approach For Struggling NASH Candidate
Galectin Offers Subgroup Approach For Struggling NASH Candidate
Stealthy NGM And Bristol Emerge As Serious NASH Competitors
Madrigal Believes It Holds The Key To NASH: Clearing The Fat
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
Combination Strategies A Common Thread In NASH R&D
Karo Bio forced to abandon Phase III-stage eprotirome

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel